EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 20-Oct-2026 10:16 ET (20-Oct-2026 14:16 GMT/UTC)

What’s next for theranostics?

Society of Nuclear Medicine and Molecular Imaging
Peer-Reviewed Publication

Theranostics is now a mature cancer treatment modality, and The Journal of Nuclear Medicine (JNM) is capturing the moment in a new supplement: “Theranostics: The State of the Art.” Guest edited by Ken Herrmann, MD, MBA, with JNM Editor-in-Chief Johannes Czernin, MD, the supplement brings together top voices in the field to map out where theranostics stands today and where it’s headed next.

Journal: Journal of Nuclear Medicine

Gene expression linked to survival differs by kidney cancer subtype

Tokyo University of Science
Peer-Reviewed Publication

A gene involved in cell signaling and lipid metabolism, CTDNEP1, is associated with poorer survival in clear cell renal cell carcinoma (ccRCC), a study from Tokyo University of Science and Nippon Medical School has found. Researchers analyzed publicly available cancer databases to examine CTDNEP1 expression in ccRCC and papillary RCC. They found that higher CTDNEP1 expression was associated with poorer survival in ccRCC, suggesting its potential as a candidate prognostic biomarker for this subtype.

Journal: Anticancer Research

Novel radiotherapy may save increasingly many rectal cancer patients from surgery and stoma

Tampere University
Reports and Proceedings

Tampere University Hospital (Tays) has begun to offer a new radiotherapy to treat rectal cancer in which an intensive dose of radiation is targeted to the tumour surface. The aim is to destroy the tumour so that increasingly many patients may avoid a massive surgery and a potentially permanent stoma. Finland is at the forefront of implementing this novel treatment.

Vienna to host EANM'26 as nuclear medicine enters a period of rapid transformation

European Association of Nuclear Medicine
Meeting Announcement

Nuclear medicine is now one of the fastest-growing fields in modern healthcare, with more than 50 million procedures performed worldwide each year. New radioactive drugs that both find and treat cancer cells are showing striking results for patients with advanced disease, and clinical trials of these treatments have more than doubled since 2015.

Does mitochondrial DNA affect cancer progression?

Wiley
Peer-Reviewed Publication

New research in The FEBS Journal found a correlation between mtDNA copy number and the extent of genetic mutations within cancer cells, suggesting that mtDNA may affect cancer severity.

Journal: FEBS Journal

Van Andel Institute’s Dr. Derek Janssens receives a New Innovator Award from the National Institutes of Health Common Fund

Van Andel Research Institute
Grant and Award Announcement

The National Institutes of Health Common Fund has selected Van Andel Institute’s Derek Janssens, Ph.D., to receive a New Innovator Award, which supports exceptional research led by early-career scientists.

Funder: National Institutes of Health Common Fund

Cancer prevention and screening takes center stage during DCSummit convened by NCCN

National Comprehensive Cancer Network
Meeting Announcement

The National Comprehensive Cancer Network^® (NCCN^®) hosted a two-day summit focused on expanding access to life-saving cancer prevention and screening. The event examined policy solutions at both the population and individual levels, with particular attention to equity, innovation, and access.

NIH honors Sylvester scientist developing cancer therapy that can evolve to outsmart tumors

University of Miami Miller School of Medicine
Grant and Award Announcement

Leor Weinberger, Ph.D., virologist and professor with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been awarded the National Institutes of Health (NIH) most prestigious award—the NIH Director’s Pioneer Award—for his “High-Risk, High-Reward Research” to develop a novel cancer therapy with the ability to mutate, or evolve, over time.

Making pediatric cancer more ‘visible’ boosts immunotherapy response

Penn State
Peer-Reviewed Publication

A new preclinical study from researchers at Penn State College of Medicine revealed blocking a specific protein makes pediatric cancer cells easier to detect and more vulnerable to treatment, potentially boosting effectiveness of cancer immunotherapy.

Journal: Autophagy
Funder: Four Diamonds, Lois High Berstler Research Endowment

Dr. Dennis Slamon awarded the 2026 Albany Prize for developing lifesaving cancer treatments

University of California - Los Angeles Health Sciences
Grant and Award Announcement

Dr. Dennis Slamon, a pioneering oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.

12
13
14
15
16